<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1382">
  <stage>Registered</stage>
  <submitdate>27/11/2006</submitdate>
  <approvaldate>27/11/2006</approvaldate>
  <nctid>NCT00404261</nctid>
  <trial_identification>
    <studytitle>Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).</studytitle>
    <scientifictitle>An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>108835</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fluticasone/Salmeterol HFA

Other: Arm 1 - Fluticasone/Salmeterol HFA MDI without counter

Other: Arm 2 - Fluticasone/Salmeterol HFA MDI with counter


Treatment: drugs: Fluticasone/Salmeterol HFA
Fluticasone/Salmeterol HFA, 2 puffs twice daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patient satisfaction questionnaires administered at baseline and at the end of treatment (day 30).</outcome>
      <timepoint>Day 30</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Healthcare professional satisfaction questionnaires administered at baseline and at the end of treatment (day 30) Patient compliance as measured by the device counter readings at the end of treatment (day 30), compared to the baseline reading.</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Healthcare professional satisfaction questionnaires Patient Compliance Safety Evaluations: adverse events</outcome>
      <timepoint>8 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Outpatient

          -  Documented physician diagnosis of asthma or COPD

          -  Requires use of a controller and long acting beta 2 agonist

          -  Ability to provided written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with life threatening asthma or COPD

          -  Historical or current evidence of significant diseases

          -  Immediate or delayed hypersensitivity to inhaled short acting beta2agonist or
             sympathomimetic drug or any component of the MDI formulation

          -  History of drug or alcohol abuse Abnormal chest x ray not consistent with asthma or
             COPD

          -  Use of supplemental oxygen; systemic corticosteroids; short acting beta2agonists other
             than VENTOLIN HFA; antibiotics for respiratory infections; anti-arrhythmics;
             anticonvulsants; central nervous system stimulants; tricyclic antidepressants and
             monoamine oxidase inhibitors.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>132</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,WA</recruitmentstate>
    <hospital>GSK Investigational Site - Auchenflower</hospital>
    <hospital>GSK Investigational Site - Caboolture</hospital>
    <hospital>GSK Investigational Site - Kippa Ring</hospital>
    <hospital>GSK Investigational Site - Perth</hospital>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the level of satisfaction experienced by asthma or
      chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol
      HFA Metered Dose Inhaler (MDI) with counter, as compared to using Fluticasone/Salmeterol HFA
      MDI without counter.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00404261</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>